Abstract:Cardiovascular disease remains a leading cause of morbidity and mortality among Americans. A significant share of all resources for health care is allocated for the diagnosis and treatment of acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Because millions of patients visit emergency departments with chest pain and other symptoms that might indicate ACS, the clinician must be familiar with appropriate diagnostic and therapeutic treatment measures. Non-ST-segment elevation (NSTE) ACS is a particularly challenging clinical entity due in part to limitations in the diagnostic tools employed to detect it and the wide range of therapeutic options available to treat it. Despite advances in the treatment of ACS and the dissemination of formal recommendations on approaches to managing NSTE ACS, pharmacologic and reperfusion therapy remain underused and often delayed. This results in an increase in adverse cardiac events for patients and rising health care costs for the public. The key to NSTE ACS management is rigorous adherence and application of evidence-based recommendations. The American Heart Association (AHA) and the American College of Cardiology (ACC) have released comprehensive clinical practice guidelines to manage NSTE ACS. These include a process of risk stratification of patients presenting with NSTE ACS or possible NSTE ACS. Risk stratification can be performed using a number of scoring models, including the Thrombolysis in Myocardial Infarction (TIMI), the Global Registry of Acute Coronary Events (GRACE), and the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) scoring models. Once a patient's risk for adverse cardiac events is determined, appropriate diagnostic and therapeutic modalities can be selected to match their level of risk. American College of Cardiology/AHA recommendations for the diagnosis and treatment of NSTE ACS include considerations regarding admission, antiplatelet therapy, anticoagulation, and early percutaneous coronary intervention/diagnostic angiography with the intent to perform revascularization. New information has emerged since the release of the 2007 updated ACC/AHA guidelines. The 2009 update of the ACC/AHA guidelines includes new recommendations on antiplatelet therapy, early invasive therapy, and the timing of glycoprotein IIb/IIIa inhibitor therapy for patients with NSTE ACS. Considering this new information during the application of the ACC/AHA guidelines will enhance selecting the optimal treatment for the NSTE ACS patient and ensure appropriate use of health care resources.

A simplified approach to the management of non–ST-segment elevation acute coronary syndromes

Clinical Analysis of 373 Patients with Non-ST Elevation Acute Coronary Syndrome in a Teaching Hospital

Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies

An update on management of the patient presenting with non-ST-elevation acute coronary syndromes

Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes

Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice

Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review

Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines

Invasive Management Strategies And Antithrombotic Treatments In Patients With Non-St-Segment-Elevation Acute Coronary Syndrome In China Findings From The Improving Ccc Project (Care For Cardiovascular Disease In China)

Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016

A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome

Utilization of early invasive management strategies for high-risk patients with non–ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement …

Performance on Management Strategies with Class I Recommendation and A Level of Evidence among Hospitalized Patients with Non-St-segment Elevation Acute Coronary Syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) Project

Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes

[Real-World Efficacy of Current Lipid-Lowering Strategies in Patients with Acute Coronary Syndrome. Time to Change the Paradigm for Treatment].

Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review

Changing the model of care for patients with acute coronary syndromes

[Long-term management of post acute coronary syndrome with oral antiplatelet therapy]